Compare · HCXY vs PEY
HCXY vs PEY
Side-by-side comparison of Hercules Capital, Inc. (HCXY) and Invesco High Yield Equity Dividend Achievers ETF (PEY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HCXY and PEY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.43B.
- HCXY has hit the wire 4 times in the past 4 weeks while PEY has been quiet.
- PEY has more recent analyst coverage (2 ratings vs 0 for HCXY).
Invesco High Yield Equity Dividend Achievers ETF
The investment seeks to track the investment results (before fees and expenses) of the NASDAQ US Dividend AchieversTM 50 Index (the "underlying index"). The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq, Inc. includes common stocks in the underlying index that have a consistent record of dividend increases, principally on the basis of dividend yield and consistent growth in dividends.
Latest HCXY
- Hercules Capital Receives Affirmed BBB- Investment Grade Corporate and Unsecured Credit Rating from Fitch Ratings, Inc.
- Hercules Capital Announces Date for Release of Third Quarter 2026 Financial Results and Conference Call
- Hercules Capital Closes Institutional Notes Offering of $400.0 Million 6.700% Notes due 2029
- Hercules Capital Prices Upsized Institutional Notes Offering of $400.0 Million 6.70% Notes due 2029
- Hercules Capital Announces the Appointment of Alfred B. Fichera to Its Board of Directors
- Hercules Capital’s Investment Adviser Surpasses $2.3 Billion in Investable Capital
- Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.
- Hercules Capital Reports Second Quarter 2026 Financial Results
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
Latest PEY
- Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details
- Earnings Scheduled For May 11, 2022
- Earnings Scheduled For March 9, 2022
- RBC Capital reiterated coverage on Peyto Exploration & Dev with a new price target
- Peyto Exploration & Dev upgraded by TD Securities with a new price target